Is CGEM overvalued right now?
Based on our 2026 models, Cullinan Therapeutics, Inc. (CGEM) appears overvalued at $18.43 with roughly 1116.9% downside versus fair value. Confirm with valuation ratios and financials before acting.
Cullinan Therapeutics, Inc. (CGEM) is currently Overvalued by 1116.86%
Instant valuation answer
Cullinan Therapeutics, Inc. (CGEM) appears overvalued by approximately 1116.86% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.
- Downside (live) 1116.86% (from live valuation API)
- Confidence (live) 8.5/10 (High conviction overvalued)
Confidence Score is based on the magnitude of upside or downside vs intrinsic value.
Fair value estimate
Unlock fair valueCurrent price
$18.43
Stock valuation checker
Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.
Explore Our Valuation Calculators
Why is Cullinan Therapeutics, Inc. overvalued or undervalued?
Based on intrinsic value, Cullinan Therapeutics, Inc. (CGEM) looks priced with a margin of safety relative to a cash-flow-based fair value that blends growth, reinvestment needs, and a risk-adjusted discount rate.
Compared to historical valuation, today’s multiple sits under the range implied by the company’s own five-year average—suggesting the market is more cautious than its own past pricing of similar fundamentals.
Market expectations embedded in the price imply a modest bar for execution: revenue cadence, margin stability, and capital returns would need to hold up to justify a sustained discount versus fair value.
Key metrics
- P/E ratio
- 38.2x
- Revenue growth (TTM y/y)
- 21%
- Profit margin
- 11.5%
- Fair value (model)
- Unlock
Frequently asked questions — CGEM
What is Cullinan Therapeutics, Inc.'s intrinsic value?
Our DCF, P/E Multiple, and P/S Multiple models estimate whether CGEM trades above or below fair value. At $18.43, Cullinan Therapeutics, Inc. currently looks overvalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.
How is Cullinan Therapeutics, Inc.'s intrinsic value calculated?
Tickerplace calculates CGEM's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.
Is CGEM undervalued right now?
A stock is undervalued when price sits below a supportable fair value range. Check whether CGEM's gap aligns with fundamentals using the ratios and financial links on this page.
Related companies — valuation
Peers for CGEM: open their overvalued / undervalued view.